2025 年 10 月 22 日， 波士顿科学（Boston Scientific，NYSE: BSX） 发布第三季度财报： 净销售额 50.65 亿美元 （报告口径 +20.3%；有机 +15.3%），调整后 EPS 0.75 美元（同比 +19%），均超出市场预期。财报发布后，公司同步上调全年销售和利润指引，股价盘前上涨。 在医疗器械行业，波士顿科学的财报长期被视作"心血管和介入治疗赛道的风向标"。这不仅因为它是全球结构性心脏病与电生理领域的头部企业之一，更在于它的 业务构成与术式渗透节奏，往往提前反映整个市场的走势。Q3 的亮眼表现，是一份超预期的业绩报告，也是一次产业趋势的实证。 一 、财报要点 ：营收与盈 利 "双 提速" ，全 年展 望上调 第三季度，波士顿科学实现 净销售额 50.65 亿美元 （约合人民币361亿） ，报告口径增长 20.3%，有机增长 15.3%。调整后每股收益为 0.75 美元，高于去年同期的 0.63 美元；GAAP EPS 为 0.51 美元。 | | | | | | Increase/(Decrease) | | | | --- | --- | --- | --- | ...

Core Insights - Boston Scientific Corp. shares increased over 4% in intra-day trading following the release of third-quarter earnings and revenue that surpassed analyst expectations, driven by strong performance across all business segments [1] Financial Performance - The company reported adjusted earnings per share (EPS) of $0.75, exceeding the consensus estimate of $0.71 [2] - Revenue grew 20.3% year-over-year to $5.07 billion, surpassing forecasts of $4.97 billion [2] - Organic revenue increased by 15.3%, exceeding the company's previous guidance range of 12% to 14% [2] Segment Performance - The Cardiovascular segment experienced significant growth, with revenue up 22.4% [2] - The MedSurg segment also showed strong performance, climbing 16.4% [2] - U.S. sales increased by 27% compared to the same quarter last year, indicating robust domestic demand [2] Future Outlook - Boston Scientific raised its full-year 2025 outlook, now anticipating adjusted EPS between $3.02 and $3.04, compared to the consensus of $2.98 [3] - For the fourth quarter, management guided for EPS between $0.77 and $0.79, above the Wall Street forecast of $0.76 [3]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Core Viewpoint - Boston Scientific (BSX.US) reported a strong performance in Q3, with sales exceeding analyst expectations and a significant year-over-year growth in revenue and adjusted earnings per share [1] Financial Performance - Q3 sales increased by 20% year-over-year to $5.07 billion, surpassing Wall Street's forecast of $4.97 billion [1] - The cardiovascular segment saw a 22% year-over-year sales growth, reaching $3.34 billion, which was above the expected $3.27 billion [1] - Adjusted earnings per share for the quarter were $0.75, exceeding the anticipated $0.71 [1] Guidance Update - The company raised its full-year adjusted earnings per share guidance to a range of $3.02 to $3.04, which is higher than the analyst consensus of $2.98 [1]

Core Insights - Boston Scientific Corporation (BSX) reported third-quarter 2025 adjusted earnings per share (EPS) of 75 cents, a 19% increase year-over-year, surpassing the Zacks Consensus Estimate by 5.6% and exceeding the company's guidance of 70-72 cents [1][8] - Total revenues for the quarter reached $5.07 billion, reflecting a 20.3% year-over-year increase on a reported basis and 19.4% on an operational basis, exceeding the Zacks Consensus Estimate by 1.9% [3][8] Revenue Breakdown - Revenue growth was driven by a 27% increase in the United States, a 2.6% rise in Europe, the Middle East and Africa (EMEA), a 17.1% increase in the Asia Pacific region, and a 10.4% rise in Latin America and Canada [4] - Organic growth, adjusted for foreign currency fluctuations and acquisitions/divestitures, was reported at 15.3% [3] Segment Performance - MedSurg segment revenues totaled $1.72 billion, up 16.4% year-over-year, with notable contributions from the Endoscopy unit ($747 million, up 9% organically), Urology ($682 million, up 5.4%), and Neuromodulation ($293 million, up 8.6%) [6] - The Cardiovascular segment generated $3.34 billion in revenues, reflecting a 22.4% increase year-over-year [7][9] Margin and Expense Analysis - Gross margin expanded by 110 basis points to 69.9%, while the cost of products sold rose by 16.1% to $1.52 billion [10] - Selling, general and administrative expenses increased by 11.5% to $1.74 billion, and research and development expenses rose by 26.3% to $514 million [11] Future Outlook - For 2025, Boston Scientific anticipates net sales growth of approximately 20% and adjusted EPS in the range of $3.02-$3.04, an increase from previous guidance [12][13] - Fourth-quarter revenue growth is projected between 14.5-16.5% on a reported basis, with adjusted earnings expected in the range of 77-79 cents per share [13][14] Strategic Developments - The company achieved several milestones, including regulatory approval in Japan for the FARAPULSE PFA System and the initiation of the AGENT DCB STANCE trial [16] - Boston Scientific completed an asset acquisition with Elutia, Inc. for the antibiotic-eluting EluPro BioEnvelope and CanGaroo Envelope [17]

Core Viewpoint - Boston Scientific reported a strong third-quarter performance with a 20% year-over-year sales growth, reaching $5.07 billion, surpassing Wall Street's expectations of $4.97 billion [1] Group 1: Financial Performance - The cardiovascular segment achieved a 22% year-over-year sales increase, totaling $3.34 billion, exceeding the anticipated $3.27 billion [1] - Adjusted earnings per share (EPS) for the quarter were $0.75, higher than the expected $0.71 [1] Group 2: Future Guidance - For the fourth quarter, the company projects EPS to be between $0.77 and $0.79, compared to analyst expectations of $0.76 [1] - The full-year adjusted EPS guidance has been raised from a range of $2.95 to $2.99 to a new range of $3.02 to $3.04, while analysts had anticipated $2.98 [1]

Boston Scientific (NYSE:BSX) Q3 2025 Earnings Call October 22, 2025 08:00 AM ET Company ParticipantsMike Mahoney - Chairman and CEODavid Roman - Managing DirectorPatrick Wood - Managing DirectorJon Monson - EVP and CFOJoanne Wuensch - Managing DirectorLauren Tengler - VP of Investor RelationsKen Stein - CMORick Wise - Managing DirectorConference Call ParticipantsPito Chickering - AnalystTravis Steed - Managing Director and Equity Research AnalystVijay Kumar - Senior Managing Director and Equity Research Ana ...

Boston Scientific (NYSE:BSX) Q3 2025 Earnings Call October 22, 2025 08:00 AM ET Company ParticipantsMike Mahoney - Chairman and CEODavid Roman - Managing DirectorPatrick Wood - Managing DirectorJon Monson - EVP and CFOJoanne Wuensch - Managing DirectorLauren Tengler - VP of Investor RelationsKen Stein - CMORick Wise - Managing DirectorConference Call ParticipantsPito Chickering - AnalystTravis Steed - Managing Director and Equity Research AnalystVijay Kumar - Senior Managing Director and Equity Research Ana ...

Boston Scientific (NYSE:BSX) Q3 2025 Earnings Call October 22, 2025 08:00 AM ET Speaker4Good morning and welcome to the Boston Scientific Third Quarter 2025 earnings call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, ...

Boston Scientific (NYSE:BSX) Q3 2025 Earnings Call October 22, 2025 08:00 AM ET Speaker0Good morning, and welcome to the Boston Scientific Third Quarter twenty twenty five Earnings Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Lauren Tangler, Vice President, Investor Relations. Please go ahead.Speaker1Thank you, Drew, and thanks to everyone for joining us. With me today are Mike Mahoney, Chairman and Chief Execut ...